Infectious disorders drug targets · 2025
A Clinical Multicenter Trial of Recombinant Human Interferon Gamma in Tuberculosis (GAM2022): Experience with the Use of Human Recombinant Interferon Gamma in TB Practice.
СтатьяМногоцентровое исследованиеКлиническое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Izosimova Veronika E, Barmina Natal'ja A, Zharikova Marija P, Alekseyev Oleg Y, Ryzhkova Oxana A, Sayfulin Marat H, Popova Natal'ja A, Andreyev Mihail A, Gagarina Svetlana G, Rysdauletova Raisa M, Kamaeva Natal'ja G, Samoylova Anastasiya G, Romanova Marija I
Аннотация
BACKGROUND: In this article, we present the results of a multicenter clinical trial of IFN-γ in patients with drug-susceptible and drug-resistant pulmonary Tuberculosis (TB) in routine clinical practice.
OBJECTIVE: This study aimed to confirm the efficacy and safety of IFN-γ administered to patients with TB.
METHODS: All patients were diagnosed with TB after being tested by bacterioscopic and molecular genetic methods and had no contraindications to standard chemotherapy.
RESULTS: Recombinant human IFN-γ proved high efficacy in multi-center clinical trial in routine TB practice.
CONCLUSION: The results show that IFN-γ is efficient and safe in the treatment of pulmonary tuberculosis. Clinical Trial Registration #: NCT06118619.
OBJECTIVE: This study aimed to confirm the efficacy and safety of IFN-γ administered to patients with TB.
METHODS: All patients were diagnosed with TB after being tested by bacterioscopic and molecular genetic methods and had no contraindications to standard chemotherapy.
RESULTS: Recombinant human IFN-γ proved high efficacy in multi-center clinical trial in routine TB practice.
CONCLUSION: The results show that IFN-γ is efficient and safe in the treatment of pulmonary tuberculosis. Clinical Trial Registration #: NCT06118619.